Heart failure (HF) is a common clinical syndrome characterized by high morbidity and frequent hospitalizations. HF is an independent and major risk factor for venous thromboembolism (VTE) and VTE occurring in patients with HF carries a worse prognosis. The present review will focus on short and long term role of anti-coagulants in prevention of venous thrombosis in HF patients. We will also be discussing the recently investigated and patented anti-coagulants which could have a role in this specific population.
http://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=22250920&site=ehost-live&scope=site
Shariff, N., Aleem, A., Levin, V., Desai, R. V., Nanda, S., Martinez, M. W., Smith SJ., & Freudenberger, R. (2012). Venous thromboembolism in patients with heart failure: in-hospital and chronic use of anti-coagulants for prevention.Recent Patents On Cardiovascular Drug Discovery, 7(1), 53-58.